Potential Role of Dexamphetamine in the Treatment of Non-alcoholic Fatty Liver Disease: Hopes and Pitfalls
Open Access
- 1 January 2021
- journal article
- Published by Touch Medical Media, Ltd. in touchREVIEWS in Endocrinology
- Vol. 1 (1)
- https://doi.org/10.17925/ee.2021.1.1.33
Abstract
Non-alcoholic fatty liver disease (NAFLD) is the most frequent cause of chronic liver disease globally; it is histologically classified into non-alcoholicKeywords
Funding Information
- This article is published under the Creative Commons Attribution Non-commercial License.
This publication has 31 references indexed in Scilit:
- Efficacy and Safety of the Farnesoid X Receptor Agonist Obeticholic Acid in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver DiseaseGastroenterology, 2013
- Amphetamine, past and present – a pharmacological and clinical perspectiveJournal of Psychopharmacology, 2013
- Metformin in non-alcoholic fatty liver disease: A systematic review and meta-analysisBiomedical Reports, 2012
- Life style modification improves insulin resistance and liver histology in patients with non-alcoholic fatty liver diseaseWorld Journal of Hepatology, 2012
- Frequency and Outcomes of Liver Transplantation for Nonalcoholic Steatohepatitis in the United StatesGastroenterology, 2011
- A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver diseaseJournal of Hepatology, 2010
- Methylphenidate and Dextroamphetamine Abuse in Substance‐Abusing AdolescentsThe American Journal on Addictions, 2004
- Nonalcoholic fatty liver disease: Improvement in liver histological analysis with weight lossJournal of Hepatology, 2004
- Pharmacotherapy for obesity: a quantitative analysis of four decades of published randomized clinical trialsInternational Journal of Obesity, 2002
- Early pharmacokinetics and clinical effects of oral d-amphetamine in normal subjectsBiological Psychiatry, 1987